![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, September 10, 2021 6:12:33 PM
HGEN's trial was for severe/critical patients, Activ5 is for moderate to critical.
Both lenzilumab Covid trials were for severe patients. No moderates or criticals in either trial.
Their p value was p=0.0365 but they had changed endpoints
The primary endpoint was changed but it was changed back to the original primary endpoint. So the trial started with vent-free survival as primary endpoint and the trial ended the trial with vent-free survival as the primary endpoint. It was an adaptive trial so changing the primary endpoint was allowed if the DSMB felt the trial was in "the promising zone".
The trial as a whole had a p value of .0365 (or .041). But the 256 patient subgroup on remdesivir with a CRP<150mg/L and under 85yo had a p value of 0.0002. In this patient population, 10.1% of lenz patients failed to go to vent free survival whereas 25.7% of placebo patients failed to go to vent-free survival for a hazard ratio of 3.22 (222% efficacy). That is now the exact patient population in the ACTIV-5 trial.
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM